Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.

@article{Slingluff2004ImmunologicAC,
  title={Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.},
  author={Craig L Slingluff and Gina R. Petroni and Galina V. Yamshchikov and Sarah Hibbitts and William W. Grosh and Kimberly A Chianese-bullock and Eric A. Bissonette and Donna L. Barnd and Donna H. Deacon and James W. Patterson and Jayashree Parekh and Patrice Y. Neese and Elizabeth M. H. Woodson and Catherine J. Wiernasz and Priscilla K Merrill},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 22},
  pages={4474-85}
}
PURPOSE A phase II trial was performed to test whether systemic low-dose interleukin-2 (IL-2) augments T-cell immune responses to a multipeptide melanoma vaccine. Forty patients with resected stage IIB-IV melanoma were randomly assigned to vaccination with four gp100- and tyrosinase-derived peptides restricted by human leukocyte antigen (HLA) -A1, HLA-A2, and HLA-A3, and a tetanus helper peptide plus IL-2 administered daily either beginning day 7 (group 1), or beginning day 28 (group 2… CONTINUE READING
59 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 59 extracted citations

Similar Papers

Loading similar papers…